Direct medical costs in a cohort of patients with breast cancer
Main Article Content
Keywords
Epidemiology, Cost of Illness, Breast Neoplasms
Abstract
Background: The economic cost of breast cancer (BC) treatment and the increase in incidence and prevalence challenges the financial stability of any healthcare system.
Objective: To determine direct medical costs (DMC) of BC treatment and factors associated with DMC.
Material and methods: Partial economic evaluation in a retrospective cohort of 160 patients with a confirmed diagnosis of BC. DMC was considered from the IMSS perspective. Bootstrapping analysis was used to deal with uncertainty and generalized linear model to identify factors associated with DCM
Results: The total average annual cost of BC treatment was $251,018 mexican pesos. In clinical stage I was $116,123, stage II $242,132, stage III $287,946, and stage IV $358,792 pesos. In progression disease, DMC were more elevate ($380,117) vs. without progression ($172,897), (p < 0.0001). In patients who died, DMC were $357,579 mexican pesos compared to those who survived ($218,699) (p < 0.0001).
Conclusions: The average annual cost of CM treatment was $251,018 pesos. DMCs increase significantly as patients present more advanced stages of the disease. Factors associated with costs were age, stages II, III and the progression of BC.
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics, 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in185 countries. CA Cancer J Clin. 2018;68(6):394-424. DOI: 10.3322/caac.21492.
Latest world cancer statistics – GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. International Agency for Research on Cancer. Disponible en: https://www.iarc.who.int/news-events/latestworld-cancer-statistics-globocan-2012-estimated-cancerincidence-mortality-and-prevalence-worldwide-in-2012/
Chavarri-Guerra Y, Villarreal-Garza C, Liedke PER, Knaul F, Mohar A, Finkelstein DM, et al. Breast cancer in Mexico: a growing challenge to health and the health system. Lancet Oncol. 2012;13(8):335-43. DOI: 10.1016/S1470-2045(12)70246-2.
Yabroff RK, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United States: Estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev. 2011;20 (10):2006-14. DOI: 10.1158/1055-9965.EPI-11-0650.
Luengo-Fernández R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a populationbased cost analysis. Lancet Oncol. 2013;14(12):1165-74. DOI: 10.1016/S1470-2045(13)70442-X.
Informe al Ejecutivo Federal y al Congreso de la Unión sobre la situación financiera y los riesgos del Instituto Mexicano del Seguro Social 2018-2019. Disponible en: http://www.imss. gob.mx/sites/all/statics/pdf/informes/20182019/21-Informe Completo.pdf.
Comisión Económica para América Latina y el Caribe (CEPAL), Estudio Económico de América Latina y el Caribe, 2020 (LC/ PUB.2020/12-P), Santiago, 2020. Disponible en: https:// www.cepal.org/es/publicaciones/46070-estudio-economicoamerica-latina-caribe-2020-principales-condicionantes.
Knaul FM, Nigenda G, Lozano R, Arreola-Ornelas H, Langer A, Frenk J. Breast cancer in Mexico: a pressing priority. Reprod Health Matters. 2008;16(32):113-23. DOI: 10.1016/ S0968-8080(08)32414-8.
Blumen H, Fitch K, Polkus V. Comparison of treatment costs for breast cancer, by tumor stage and type of service. Am Health Drug Benefits. 2016;9(1):23-32.
Zarate Victor. Evaluaciones económicas en salud: Conceptos básicos y clasificación. Rev Méd Chile. 2010;138(Supl 2):93-7.
Prieto L, Sacristan JA, Pinto JL, Badia X, Antoñanzas F, del Llano J. Análisis de costes y resultados en la evaluación económica de las intervenciones sanitarias. Med Clin (Barc). 2004;122(11):423-9.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. editores AJCC Cancer Staging Manual. 7a ed. New York: Springer; 2010. 347-76 p.
Guía para la conducción de estudios de evaluación económica para la actualización del cuadro básico y catálogo de insumos del sector salud en México. Disponible en: ttp://www.csg. gob.mx/descargas/pdf/priorizacion/cuadro-basico/guias/ conduccion_estudios/GCEEE_2017_Diciembre_x1x.pdf.
Dirección de Administración, Unidad de Administración, Coordinación de Control de Abasto. Portal de Control del Abasto. [Disponible solo para personal autorizado en: portalcca.imss.gob.mx].
Diario Oficial de la Federación, Órgano del Gobierno Constitucional de los Estados Unidos Mexicanos. México, Distrito Federal, 22 de marzo de 2019; Acuerdo ACDO. AS3.HCT.270219/90.P.DF. [Internet] Disponible en: https:// www.dof.gob.mx/nota_detalle.php?codigo=5554895&fec ha=22/03/2019.
Knaul FM, Arreola-Ornelas H, Velázquez E, Dorantes J, Méndez O, Ávila-Burgos L. El costo de la atención médica del cáncer mamario: el caso del Instituto Mexicano del Seguro Social. Salud Publica Mex. 2009;51(Supl 2):S286-95. DOI: 10.1590/s0036-36342009000800019.
Radice D, Redaelli A. Breast cancer management. Pharmacoeconomics. 2003;21(6):383-96. DOI: 10.2165/ 00019053-200321060-00003.
Barron JJ, Quimbo R, Nikam PT, Amonkar MM. Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat. 2008;109(2):367-77. DOI: 10.1007/s10549-007-9650-4.
Blumen H, Fitch K, Polkus V. Comparison of treatment costs for breast cancer, by tumor stage and type of service. Am Health Drug Benefits. 2016;9(1):23-32. PMCID: PMC4822976.
Meneses-García A, Ramirez T, Ruiz-Godoy L, Chiquete E, Mohar A. Costs of breast cancer treatment prior to the introduction of inmune-based theraphy in México. Rev Med Inst Mex Seguro Soc. 2012;50(1):19-24. PMID: 22768813.
Diaby V, Tawk R, Sanogo V, Xiao H, Montero AJ. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast Cancer Res Treat. 2015;151(1):27-40. DOI: 10.1007/s10549-015-3383-6.
Francisci S, Guzzinati S, Capodaglio G, Pierannunzio D, Mallone S, Tavilla A, et al. Patterns of care and cost profiles of women with breast cancer in Italy: EPICOST study based on real world data. Eur J Healt Econ. 2020;21(7):1003-13. DOI: 10.1007/s10198-020-01190-z.
Berkowitz N, Gupta S, Silberman G. Estimates of the lifetime direct cost of treatment for metastasic breast cancer. Value Health. 2000;3(1):23-30. DOI: 10.1046/j.1524-4733.2000.31003.x 24.
Sun L, Legood R, Dos-Santos-Silva I, Gaiha SM, Sadique Z. Global treatment costs of breast cancer by stage: A systematic review. PLoS One. 2018;13(11):e0207993. DOI: 10.1371/journal.pone.0207993.
Capri S, Russo A. Cost of breast cancer based on real-world data: a cancer registry study in Italy. BMC Health Serv Res. 2017;17(1):84. DOI: 10.1186/s12913-017-2006-9.
Montero AJ, Eapen S, Gorin B, Adler P. The economic burden of metastatic breast cancer: a U.S. managed care perspective. Breast Cancer Res Treat. 2012;134(2):815-22. DOI: 10.1007/ s10549-012-2097-2.
Bright K, Barghash M, Donach M, Gutierrez-de la Barrera M, Schneider RJ, Formenti SC. The role of health system factors in delaying final diagnosis and treatment of breast cancer in Mexico City, Mexico. Breast. 2011;20(Suppl 2):S54-9. DOI: 10.1016/j.breast.2011.02.012.
Trufelli DC, da Costa-Miranda V, Brisola-Dos Santos MB, Moreno-Perez Fraile N, Guedes-Pecoroni P, Ribeiro-Gonzaga SF, et al. [Analysis of delays in diagnosis and treatment of breast cancer patients at a public hospital]. [Artículo en portugués] Rev Assoc Med Bras. 2008;54(1):72-6. DOI: 10.1590/s0104-42302008000100024.
Rodrigues-Rezende MC, Augusto-Koch H, de AlmeidaFigueiredo J, Santos-Thuler LC. [Factors leading to delay in obtaining definitive diagnosis of suspicious lesions for breast cancer in a dedicated health unit in Rio de Janeiro]. [Artículo en portugués] Rev Bras Ginecol Obstet. 2009;31(2):75-81. DOI: 10.1590/s0100-72032009000200005.
Romanoff A, Hayes-Constant T, Johnson KM, CedanoGuadianos M, Burga-Vega AM, Zunt J, et al. Association of previous clinical breast examination with reduce delays and earlier-stage breast cancer diagnosis among women in Peru. JAMA Oncol. 2017;3(11):1563-7. DOI: 10.1001/ jamaoncol.2017.1023.
Richards MA, Smith P, Ramirez AJ, Fentiman IS, Rubens RD. The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Br J Cancer. 1999; 79(5-6):858-64. DOI: 10.1038/sj.bjc.6690137.
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.
Karla de la Cruz-Aguirre, <p>Instituto Mexicano del Seguro Social, Centro Médico Nacional de Occidente, Hospital de Gineco-Obstetricia “Lic. Ignacio García Tellez”, Servicio de Oncología Médica. Guadalajara, Jalisco, México </p>
Médico Especialista en Ginecología y Obstetricia
Laura Cortés-Sanabria, <p>Instituto Mexicano del Seguro Social, Centro Médico Nacional de Occidente, Hospital de Especialidades “Lic. Ignacio García Tellez”, Unidad de Investigación Biomédica “02” , Guadalajara, Jalisco, México</p>
Doctora en Ciencias de la Salud Pública por la Universidad de Guadalajara
Maestra en Economía de la Salud por la Universidad Pompeu-Fabra de Barcelona, España
Médico Especialista en Medicina Interna
Investigador Asociado, Instituto Mexicano del Seguro Social, Centro Médico Nacional de Occidente, Hospital de Especialidades “Lic. Ignacio García Tellez”, Unidad de Investigación Biomédica “02” , Ciudad de Guadalajara, México.
Miembro del Sistema Nacional de Investigadores, SNI 2
Efraín Salas-González, <p>Instituto Mexicano del Seguro Social, Centro Médico Nacional de Occidente, Hospital de Gineco-Obstetricia “Lic. Ignacio García Tellez”, Servicio de Oncología Médica. Guadalajara, Jalisco, México </p>
Médico Especialista en Oncología Médica
José Luis Canales-Muñoz, <p>Instituto Mexicano del Seguro Social, Delegación Jalisco, Jefatura de Prestaciones Médicas, Guadalajara, Jalisco, México</p>
Médico Especialista en Epidemiología
Doctorado en Ciencias de la Salud Pública
Guadalupe Aguayo-Alcaraz, <p>Instituto Mexicano del Seguro Social, Centro Médico Nacional de Occidente, Hospital de Gineco-Obstetricia “Lic. Ignacio García Tellez”, Servicio de Oncología Médica. Guadalajara, Jalisco, México</p>
Maestra en Ciencias de la Salud Pública
Rafael Adalid Ayala-Cortés, <p>Instituto Mexicano del Seguro Social, Centro Médico Nacional de Occidente, Hospital de Especialidades “Lic. Ignacio García Tellez”, Unidad de Investigación Biomédica “02” , Guadalajara, Jalisco, México</p>
Medico Residente
Carmen Yuritzi Palomares-Hernández, <p>Instituto Mexicano del Seguro Social, Centro Médico Nacional de Occidente, Hospital de Especialidades “Lic. Ignacio García Tellez”, Unidad de Investigación Biomédica “02” , Guadalajara, Jalisco, México</p>
Medico Pasante de Servicio Social en Investigación